Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Reuters

2025/08/25

Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio

Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562242618"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562242618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562242618?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562242618","market":"us","top_or_hot":-1,"title":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-25 21:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADTX","symbol_name":"ADiTx Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDLb9mb6D:1","article_id":"2562242618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562242618","pubTimestamp":1756127723,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADTX":"ADiTx Therapeutics","BK4139":"生物科技"},"translate_title":"ADiTx Inc.的子公司Adimune凭借强大的专利组合推进免疫系统重编程","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADTX":0.9},"content_text":"Adimune, Subsidiary of ADiTx Inc., Advances Immune System Reprogramming with Robust Patent Portfolio\n    \n\n        Aditxt, Inc., a company known for accelerating promising health innovations, has provided an update on its wholly owned subsidiary, Adimune, Inc. Adimune is pioneering a DNA-based therapeutic platform aimed at reprogramming the immune system. With a strong intellectual property portfolio consisting of 96 granted and 22 pending patents, Adimune is strategically positioned to address the global autoimmune therapeutics market, projected to exceed $160 billion by 2030. The company plans to seek FDA submission for first-in-human trials targeting type 1 diabetes and stiff person syndrome by early 2026. Adimune's platform seeks to restore immune tolerance without chronic immunosuppression, potentially transforming treatment approaches for conditions like type 1 diabetes, psoriasis, and stiff person syndrome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250825106664) on August 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}